Susana Diego
Overview
Explore the profile of Susana Diego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morato X, Marquie M, Tartari J, Lafuente A, Abdelnour C, Alegret M, et al.
Sci Rep
. 2023 Apr;
13(1):5406.
PMID: 37012306
Although beta-amyloid (Aβ) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer's disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation...
2.
Rosende-Roca M, Abdelnour C, Esteban E, Tartari J, Alarcon E, Martinez-Atienza J, et al.
Alzheimers Res Ther
. 2021 May;
13(1):95.
PMID: 33952308
Background: Alzheimer disease (AD) is a progressive neurodegenerative disorder affecting the elderly with a prevalence of 7.1% in women and 3.3% in men. Sex-related patterns have been reported in prognosis,...
3.
Abdelnour C, Esteban de Antonio E, Perez-Cordon A, Lafuente A, Buendia M, Pancho A, et al.
J Alzheimers Dis
. 2020 Sep;
77(4):1805-1813.
PMID: 32986671
Background: The COVID-19 pandemic has brought great disruption to health systems worldwide. This affected ongoing clinical research, particularly among those most vulnerable to the pandemic, like dementia patients. Fundació ACE...
4.
Ciudin A, Simo-Servat O, Hernandez C, Arcos G, Diego S, Sanabria A, et al.
Diabetes
. 2017 Sep;
66(12):3098-3104.
PMID: 28951388
Type 2 diabetes is associated with a high risk of cognitive impairment and dementia. Therefore, strategies are needed to identify patients who are at risk for dementia. Given that the...
5.
Abdelnour C, Rodriguez-Gomez O, Alegret M, Valero S, Moreno-Grau S, Sanabria A, et al.
J Alzheimers Dis
. 2017 Mar;
57(2):625-632.
PMID: 28269773
Background: Recruitment methods can determine sample characteristics in mild cognitive impairment and Alzheimer's disease dementia, but little is known about its influence in subjective cognitive decline (SCD). Objective: To determine...
6.
Ibarria M, Alegret M, Valero S, Morera A, Guitart M, Canabate P, et al.
J Alzheimers Dis
. 2016 Jan;
50(2):559-66.
PMID: 26757182
Background: The existing pharmacological treatments for Alzheimer's disease (AD) can only slow the progression of symptoms or delay admission to long-term care facilities. The beneficial effects of non-drug treatments are...